Related Experiment Video
Updated: May 9, 2026
06:35
Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres
Published on: February 2, 2015
Botulinum toxin treatment in glaucomatous patients: a pilot study
A Librando1, V Russo, M Tarallo
1Department of Sense Organs, Sapienza University of Rome, Rome, Italy.
European Review for Medical and Pharmacological Sciences
|July 16, 2013
Summary
Botulinum toxin injections (BTI) effectively treat iatrogenic entropion (IE) in primary open angle glaucoma (POAG) patients using prostaglandin analogues. This treatment showed significant improvement in most patients, offering a viable therapeutic option.
Area of Science:
- Ophthalmology
- Glaucoma Treatment
- Oculoplastics
Background:
- Iatrogenic entropion (IE) is a potential complication in patients with primary open angle glaucoma (POAG) undergoing treatment.
- Prostaglandin analogues (PA) are commonly used for POAG management and may contribute to IE.
- Effective treatment options for IE in this patient population are crucial.
Purpose of the Study:
- To evaluate the efficacy of botulinum toxin injections (BTI) for treating iatrogenic entropion (IE).
- To assess BTI as a treatment for patients with primary open angle glaucoma (POAG) using prostaglandin analogues (PA).
Main Methods:
- A study involving 20 patients with POAG and IE, treated with prostaglandin analogues.
- Botulinum toxin injections (BTI) were administered into the lower orbicularis muscle.
- Treatment outcomes were evaluated using a 0-6 point rating scale.
Main Results:
- Significant improvement in iatrogenic entropion (IE) was observed in 18 out of 20 patients.
- The average rating for treatment effectiveness was 5.37 points on a 0-6 scale.
- Two patients experienced only slight improvement.
Conclusions:
- Botulinum toxin injections (BTI) are a successful treatment for iatrogenic entropion (IE) caused by glaucoma therapy with prostaglandin analogues (PA).
- BTI offers a temporary yet effective therapeutic solution for this specific patient group.
- Treatment targets the orbicularis muscle to correct entropion.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...